SCHEMBL30925573

SCHEMBL30925573

Cc1cccnc1S(=O)(=O)Nc1cccc2cc(N3CCOCC3)cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 12/20 0.47
▸ TDP1 Q9NUW8 5/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ OPRK1 P41145 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ AGTR1 P30556 2/20 0.43
▸ MITF O75030 1/20 0.43
▸ S1PR4 O95977 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ S1PR1 P21453 1/20 0.43
▸ CKS1B P61024 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ GLO1 Q04760 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214195 1.00 SLC40A1 (0.47) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL27214297 0.85 MET (0.49) SLC40A1KMT2AMEN1ALDH1A1HTT
SCHEMBL30925479 0.85 MET (0.49) SLC40A1KMT2AMEN1ALDH1A1HTT
SCHEMBL27214253 0.82 SLC40A1 (0.48) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL30925406 0.82 SLC40A1 (0.48) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL30925569 0.80 SLC40A1 (0.67) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL27214172 0.80 SLC40A1 (0.67) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL27214328 0.77 SLC40A1 (0.73) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL30925535 0.77 SLC40A1 (0.73) SLC40A1TDP1KMT2AMEN1OPRK1
SCHEMBL30553475 0.77 SLC40A1 (0.51) SLC40A1TDP1KMT2AMEN1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885TDP1 4247/4885KMT2A 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback